Join our daily newsletter At The Bell to receive exclusive market insights
- Universal Biosensors (UBI) has entered an exclusive agreement with U.S.-based Lubris Biopharma for the supply of Lubricin for UBI’s diagnostic products
- Under the perpetual supply agreement, Lubris is set to supply its version of the human protein Lubricin to UBI for use in its electrochemical biosensor technologies
- Lubricin (PRG4) is described by UBI as an innovative antifouling coating that is said to enhance specificity and sensitivity by up to one million times when applied through its diagnostic products
- Universal Biosenors Chief Executive Officer John Sharman described the supply agreement as a “generational advancement”
- Universal Biosensor’s share price has risen 36.8 per cent to trade at 65 cents this morning
Universal Biosensors (UBI) has entered an exclusive agreement with U.S.-based Lubris Biopharma for the supply of Lubricin for UBI’s diagnostic products.
Information regarding the supply agreement was light on in details, however, the company did reveal that in the event UBI manages to commercialise a product using Lubricin, the supply agreement could become non-exclusive.
Lubris is a life sciences company producing and aiming to commercialise a
version of the human protein, known as Lubricin.
Lubricin (PRG4) is described by UBI as an innovative antifouling coating that is said to enhance specificity and sensitivity by up to one million times when applied to UBI’s electrochemical biosensor technology.
The ASX-lister says it has proven that by using Lubricin its electrochemical biosensor platform can accurately detect a signal at 200 picomolar and expects
Lubricin could also be used more broadly to detect other analytes of interest.
Universal Biosenors Chief Executive Officer John Sharman described the supply agreement as a “generational advancement”.
“Our strategy is to partner with companies that have developed biosensors in large markets which can be used on our hand-held platform technology,” he commented.
Universal Biosensor’s share price has risen 36.8 per cent to trade at 65 cents at 11:38 am AEST.
